Vaxil Bio Ltd V.VXL

Alternate Symbol(s): VXLLF

Healthcare Biotechnology

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.

TSXV:VXL - Post by User

Vaxil Bio Ltd > Chinese coronavirus vaccine entering final phase of human te

<< Previous

Bullboard Posts

Next >>

Comment by bligickaon Jun 29, 2020 10:03am

51 Views

Post# 31202457

RE:Chinese coronavirus vaccine entering final phase of human te

If Goren would have done the pp at .175 when we were trading in the mid 20s the whole pp would be past us instead they waited till the share price was much lower and then priced the pp at .085 ........now it may be too late with other pharma companies moving into final stages of approval

bligicka wrote:
Chinese coronavirus vaccine entering final phase of human testing

Posted on June 28, 2020 by Adrian Gonzalez

A Chinese-owned developer’s coronavirus vaccine is entering the final stages of human testing. This means that it has the potential to get on the market soon. The China National Biotec Group (CNBG) and the United Arab Emirates (UAE) announced the collaboration on Tuesday.

Vaccines go through phases of human testing in order to analyze safety and effectiveness. There are three phases. Phase 3 trials are happening in the UAE, after being approved by the UAE Ministry of Health. Phase 2 trials recently proved that the vaccine was safe and produced high levels of antibodies.

Many Chinese developers are looking for countries overseas to test their vaccines. This is because of the dwindling number of coronavirus infections in China. CanSino Biologics and Sinovac Biotech are conducting research in Canada and Brazil, respectively. This is because these final trials require thousands of participants.

CNBG is partnering with G42 to conduct the trial and manage local distribution. CNBG is the first Chinese coronavirus vaccine developer to enter the last stretch in the path to approval. Oxford and AstraZeneca’s vaccine was the first worldwide.

China has reported 83k coronavirus infections and 4,000 deaths.